Balancing Risk and Opportunity to Choose Winning Therapies

MedCity News  |  July 28, 2024

“While FDA approval has long been a singular prize, companies should also mine their assets for the strongest commercial opportunities. …the ability to take a drug to market is an important milestone, but it is not the entire picture. To truly move the needle, both clinically and commercially, biopharma companies must fine-tune their teams, approaches and incentives to produce unique and innovative products.”

Read more from Leslie Orne’s new op-ed in MedCity News entitled, “Balancing Risk and Opportunities to Choose Winning Therapies.”